Adoptive transfer of T-cell immunity

Trends in Immunology

Volumn 23, Issue 5, 2002, Pages 264-269

  Kessels, Helmut W H G ^a   Wolkers, Monika C ^a   Schumacher, Ton N M ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MINOR HISTOCOMPATIBILITY ANTIGEN; T LYMPHOCYTE RECEPTOR; TETRAMER;

ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ALLOTRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CELL ISOLATION; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; GENE TRANSFER; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; RECEPTOR SENSITIVITY; REVIEW; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR GROWTH; TUMOR IMMUNITY;

ADOPTIVE TRANSFER; ANIMALS; AUTOANTIGENS; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HUMANS; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 0036571418     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(02)02219-6     Document Type: Review

References (66)

1. The epidemiology of acquired immunodeficiency syndrome malignancies
2. IFN-γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
3. Altered peptide ligand vaccination with Flt3-ligand-expanded dendritic cells for tumor immunotherapy
4. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
5. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
6. Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial
7. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
8. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
9. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone-marrow transplantation
10. Graft-versus-leukemia effect of donor-lymphocyte transfusions in marrow-grafted patients
11. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
12. +T-cell-based immunotherapy interferes with liver tumor progression in a transgenic mouse model
13. Adoptive immunotherapy prevents prostate cancer in a transgenic animal model
14. Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T-antigen transgenic mice
15. Tracing and characterization of the low-avidity self-specific T-cell repertoire
16. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self-tolerance on the TCR repertoire
17. +T lymphocytes that persist after peripheral tolerance to a self-antigen expressed in the pancreas
18. Low-avidity recognition of self-antigen by T cells permits escape from central tolerance
19. Self-antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy
20. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
21. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3
22. The graft-versus-leukemia effects of allogeneic cell therapy
23. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias
24. Graft-versus-leukemia reactions after bone-marrow transplantation
25. A minor transplantation antigen detected by MHC-restricted cytotoxic T lymphocytes during graft-versus-host disease
26. Identical-twin bone-marrow transplants for leukemia
27. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T-lymphocyte-defined non-MHC antigens
28. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution
29. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone-marrow transplantation
30. Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation
31. A human minor histocompatibility antigen specific for B-cell acute lymphoblastic leukemia
32. Adoptive transfer of minor-histocompatibility-antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease
33. Phenotypic analysis of antigen-specific T lymphocytes
34. Tetrameric HLA class I minor histocompatibility antigen peptide complexes demonstrate minor-histocompatibility-antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease
35. Immunocytochemical and flow-cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells
36. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia
37. In vivo tracking of tumor-specific T cells
38. Adoptive cellular immunotherapy for EBV lymphoproliferative disease
39. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr-virus-induced lymphoma in allogeneic transplant recipients
40. Complete remission of accelerated-phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes
41. Melanocyte destruction after antigen-specific immunotherapy of melanoma. Direct evidence of T-cell-mediated vitiligo
42. Transfer of specificity by murine α and β T-cell receptor genes
43. Retargeting of a T-cell line by anti-MAGE-3/HLA-A2αβTCR gene transfer
44. Functional reconstitution of class II MHC-restricted T-cell immunity mediated by retroviral transfer of the αβ TCR complex
45. Dual HLA class-I-and class-II-restricted recognition of alloreactive T lymphocytes mediated by a single T-cell receptor complex
46. Retroviral transduction of a T-cell receptor specific for an Epstein-Barr-virus-encoded peptide
47. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes
48. Efficient transfer of a tumor-antigen-reactive TCR to human peripheral-blood lymphocytes confers anti-tumor reactivity
49. Immunotherapy through TCR gene transfer
50. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ξ subunits of the immunoglobulin and T-cell receptors
51. Adoptive transfer of in-vitro-targeted, activated T lymphocytes results in total tumor regression
52. Functional expression of chimeric receptor genes in human T cells
53. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRξ/CD28 receptor
54. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immunogene therapy
55. From cancer genomics to cancer immunotherapy: Toward second-generation tumor antigens
56. Self-tolerance is H-2-restricted
57. Evidence fromin vitro studies that tolerance to self-antigens is MHC-restricted
58. On the nature of peptides involved in T-cell alloreactivity
59. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: Reagents for tumor immunotherapy
60. Immunotherapy with CTLs restricted by nonself MHC
61. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer
62. Selection of phage antibodies by binding affinity. Mimicking affinity maturation
63. In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library
64. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity
65. In vitro evolution of a T-cell receptor with high affinity for peptide/MHC
66. Changing T-cell specificity by retroviral T-cell receptor display